Regular Articles
Salmonella Effector AvrA Regulation of Colonic Epithelial Cell Inflammation by Deubiquitination

https://doi.org/10.2353/ajpath.2007.070220Get rights and content

AvrA is a newly described bacterial effector existing in Salmonella. Here, we test the hypothesis that AvrA is a deubiquitinase that removes ubiquitin from two inhibitors of the nuclear factor-κB (NF-κB) pathway, IκBα and β-catenin, thereby inhibiting the inflammatory responses of the host. The role of AvrA was assessed in intestinal epithelial cell models and in mouse models infected with AvrA-deficient and -sufficient Salmonella strains. We also purified AvrA and AvrA mutant proteins and characterized their deubiquitinase activity in a cell-free system. We investigated target gene and inflammatory cytokine expression, as well as effects on epithelial cell proliferation and apoptosis induced by AvrA-deficient and -sufficient bacterial strains in vivo. Our results show that AvrA blocks degradation of IκBα and β-catenin in epithelial cells. AvrA deubiquitinates IκBα, which blocks its degradation and leads to the inhibition of NF-κB activation. Target genes of the NF-κB pathway, such as interleukin-6, were correspondingly down-regulated during bacterial infection with Salmonella expressing AvrA. AvrA also deubiquitinates and thus blocks degradation of β-catenin. Target genes of the β-catenin pathway, such as c-myc and cyclinD1, were correspondingly up-regulated with AvrA expression. Increased β-catenin further negatively regulates the NF-κB pathway. Our findings suggest an important role for AvrA in regulating host inflammatory responses through NF-κB and β-catenin pathways.

Cited by (0)

Supported by DK-35932 to James L. Madara (The University of Chicago, Chicago, IL), National Institute of Child Health and Human DevelopmentK08 HD43839 to E.C.C., and the Pilot & Feasibility AwardDK-42086 and National Institute of Diabetes and Digestive and Kidney DiseasesKO1 DK075386 to J.S.

View Abstract